跳到正文
原文
NEJM 新英格兰医学杂志· Georgina V. Long Muhammad A. Khattak Helen J. Gogas Dirk Schadendorf Ana Arance Matteo S. Carlino Piotr Rutkowski Gareth Rivalland Antoni Ribas Janice M. Mehnert Patrick A. Ott Reinhard Dummer Paola Queirolo Christoffer Gebhardt Caroline Dutriaux Carlos Rojas Yuanbin Chen Lisa M. Tachiki Ronnie Shapira-Frommer Oliver Bechter Ryan J. Sullivan Alexander M.M. Eggermont Laureen S. Ojalvo Michelle Brown Jinchun Zhang Dmitri O. Grebennik Mizuho Fukunaga-Kalabis Paolo A. Ascierto and Michele Del Vecchiothe INTerpath-001 Investigators*·· 9 天前AI 评分50

某药联合帕博利珠单抗用于切除后IIIB至IV期黑色素瘤

Intismeran Autogene plus Pembrolizumab for Resected Stage IIB to IV Melanoma

AI 导读

某药联合帕博利珠单抗在切除后IIIB至IV期黑色素瘤患者中的初步结果显示了良好的疗效和安全性,为该适应症提供了新证据。

来源:NEJM 新英格兰医学杂志 · nejm.org